Merrimack Pharmaceuticals Stock (NASDAQ:MACK)

Ownership Financials Chart

Previous Close

$15.13

52W Range

$11.53 - $15.89

50D Avg

$14.80

200D Avg

$13.36

Market Cap

$223.97M

Avg Vol (3M)

$182.63K

Beta

1.42

Div Yield

$15.10 (99.70%)

MACK Company Profile

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

-

IPO Date

Mar 29, 2012

Website

MACK Performance

MACK Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-2.04M	$-1.73M	$-2.47M
Net Income	$-1.16M	$-1.54M	$-2.46M
EBITDA	$-2.04M	$-2.62M	$-2.76M
Basic EPS	$-0.08	$-0.11	$-0.18
Diluted EPS	$-0.08	$-0.11	$-0.18

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q3 18Nov 07, 18 | 12:04 PM

Q2 18Aug 07, 18 | 12:33 PM

Q1 18May 08, 18 | 9:52 AM

Peer Comparison

Ticker	Company
CLDX	Celldex Therapeutics, Inc.
PBYI	Puma Biotechnology, Inc.
AGIO	Agios Pharmaceuticals, Inc.
FOLD	Amicus Therapeutics, Inc.